ArticleBriefings in bioinformatics2026
SGAC: a graph neural network framework for imbalanced and structure-aware AMP classification.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A unified framework for potency-oriented AMP discovery via multi-modal learning and guided sequence synthesis.PLoS computational biology · 2026Article
- A dual diffusion model-based representation learning framework for antimicrobial peptides classification.Bioinformatics (Oxford, England) · 2026Article
- Recent advances in computational antimicrobial peptide discovery through big data, modeling, and artificial intelligence and their interplay in ushering the next golden era of drug development.Frontiers in bioinformatics · 2026Review
- ProtoMol: enhancing molecular property prediction via prototype-guided multimodal learning.Briefings in bioinformatics · 2025Article
- Cross-attention graph neural networks for inferring gene regulatory networks with skewed degree distribution.BMC bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classifying antimicrobial peptides (AMPs) from the vast collection of peptides derived from metagenomic sequencing offers a promising avenue for combating antibiotic resistance. However, most existing AMP classification methods rely primarily on sequence-based representations and fail to capture the spatial structural information critical for accurate identification. Although recent graph-based approaches attempt to incorporate structural information, they typically construct residue- or atom-level graphs that introduce redundant atomic details and increase structural complexity. Furthermore, the class imbalance between the small number of known AMPs and the abundant non-AMPs significantly hinders predictive performance. To address these challenges, we employ lightweight OmegaFold to predict the 3D structures of peptides and construct peptide graphs using C$_\alpha $ atoms to capture their backbone geometry and spatial topology. Building on this representation, we propose the spatial graph neural network (GNN)-based AMP classifier (SGAC), a novel framework that leverages GNNs to extract structural features and generate discriminative graph representations. To handle class imbalance, SGAC incorporates weight-enhanced contrastive learning to cluster structurally similar peptides and separate dissimilar ones through adaptive weighting, and applies weight-enhanced pseudo-label distillation to generate high-confidence pseudo labels for unlabeled samples, achieving balanced and consistent representation learning. Experiments on publicly available AMP and non-AMP datasets demonstrate that SGAC significantly achieves state-of-the-art performance compared to baselines. The complete code and dataset are available at: https://github.com/wyxwyx46941930/SGAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.